Cerus Showcases Pathogen Reduction Tech at 2026 AABB Meeting

Event summary

Cerus to host workshop on INTERCEPT Platelets and Fibrinogen Complex at 2026 AABB Annual Meeting in Atlanta (Oct 17-19).
Grady Health System to present real-world implementation case study during Cerus-sponsored session.
Company to present 10 scientific abstracts on pathogen reduction technologies.
Cerus red blood cell system under regulatory review in Europe, late-stage U.S. trials.

The big picture

Cerus' strong presence at the 2026 AABB meeting underscores its leadership position in blood pathogen reduction. The focus on real-world implementation data comes as the company seeks to expand its product portfolio beyond platelets and plasma to include red blood cells. With regulatory approvals pending in major markets, Cerus appears positioned to capitalize on growing demand for safer blood products in transfusion medicine.

What we're watching

Regulatory Progress: The pace at which Cerus' red blood cell system gains approvals in key markets.
Market Adoption: Whether real-world case studies like Grady Health System's presentation accelerate hospital adoption.
Technological Edge: How Cerus' LED illuminator technology differentiates against potential competitors.